A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance.
A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance.
复制标题
Sinemet CR4 和标准 Sinemet 25/100 在帕金森病和运动能力波动患者中的双盲交叉比较。
DOI：
10.1136/jnnp.52.2.207
复制
发表时间：
1989
期刊：
影响因子：
--
通讯作者：
McDowell,FH
中科院分区：
文献类型：
--
作者：
Cedarbaum,JM;Hoey,M;McDowell,FH
14名左旋多巴治疗反应波动的帕金森病患者完成了左旋多巴/卡比多巴控释剂(Sinemet CR4)与标准Sinemet 25/100(STD)的双盲交叉试验。注意到平均剂量间隔和醒着的一天中花在“开”上的百分比显著增加，以及每日用药剂量和“关”发作的次数减少。在这项研究的双盲部分，相对于STD的开放治疗，10名患者在服用CR4时认为自己得到了改善，而只有3名患者认为自己在接受STD治疗时有所改善。使用CR4的困难包括抗帕金森效应开始的“滞后时间”增加，在一天中晚些时候出现越来越严重的运动障碍的倾向，以及运动反应的可预测性有所降低。尽管如此，由于全天的整体运动功能水平与STD相当或更好，但用药次数较少，Sinemet CR4应该被证明是一种有效的抗帕金森病药物。
Fourteen Parkinsonian patients with fluctuations in therapeutic response to levodopa completed a double-blind, crossover trial of controlled-release levodopa/carbidopa (Sinemet CR4) vs standard Sinemet 25/100 (STD). Significant increases in mean interdose interval and per cent of the waking day spent "on", as well as reductions in the number of daily medication doses and number of "off" episodes were noted. In the double-blind part of the study, relative to open treatment with STD, ten patients rated themselves as improved while taking CR4, whereas only three considered themselves improved with STD. Difficulties using CR4 included an increased "lag-time" to the onset of antiparkinson effect, a tendency to produce increasingly severe dyskinesia late in the day, and a somewhat lessened predictability of motor response. Nonetheless, since the overall level of motor function through the day was equal to or better than that attained with STD, but with fewer medication administrations, Sinemet CR4 should prove a useful antiparkinsonian agent.